Ionis Pharmaceuticals Completes Rule 144A Offering of $500 Million of Convertible Senior Notes

San Diego – December 2, 2014 – Cooley advised Ionis Pharmaceuticals, Inc. on its Rule 144A offering of $500 million aggregate principal amount of convertible senior notes due 2021. The initial purchasers have purchased $15 million aggregate principal amount of convertible notes.

Ionis is the leading company in antisense drug discovery and development; exploiting a proven, novel drug discovery platform designed to generate a pipeline of first-in-class drugs.

The Cooley team advising Ionis Pharmaceuticals was led by partners Charlie Kim, Gian-Michele a Marca and Sean Clayton, and included associates Jon Russo, Jason Savich, Phillip McGill and Adrienne Directo. Critical support was also provided by partner Natasha Leskovsek (health care and life sciences regulatory); and partners Susan Cooper Philpot and Mark Windfeld-Hansen (tax).

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has 800 lawyers across 11 offices in the United States and China.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.